|
US7147851B1
(en)
*
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7090845B2
(en)
*
|
1998-05-13 |
2006-08-15 |
Genentech, Inc. |
Diagnosis and treatment of hepatic disorders
|
|
AU2011226857B2
(en)
*
|
1998-05-13 |
2013-09-19 |
Genentech, Inc. |
Diagnosis and treatment of hepatic disorders
|
|
CA2352963A1
(en)
*
|
1998-11-25 |
2000-06-02 |
The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services |
Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
|
|
ATE298249T1
(de)
*
|
1999-04-22 |
2005-07-15 |
Biogen Idec Inc |
Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha- 4 untereinheit
|
|
US20010046496A1
(en)
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
|
AU2006220426B2
(en)
*
|
2000-04-14 |
2008-10-30 |
Genentech Inc. |
Method of administering an antibody
|
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
WO2003051393A2
(en)
*
|
2001-12-17 |
2003-06-26 |
University Of Wales College Of Medicine |
Enzymatic cleavable reagents for specific delivery to disease sites
|
|
AU2003210802B2
(en)
|
2002-02-05 |
2009-09-10 |
Genentech Inc. |
Protein purification
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
KR100788093B1
(ko)
|
2002-04-26 |
2007-12-21 |
제넨테크, 인크. |
단백질의 비친화성 정제
|
|
HUE030806T2
(hu)
|
2002-05-02 |
2017-05-29 |
Wyeth Holdings Llc |
Calicheamicin származék-hordozó konjugátumok
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
EP2368578A1
(en)
*
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
KR20050118669A
(ko)
*
|
2003-02-01 |
2005-12-19 |
뉴랄랩 리미티드 |
가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
|
|
LT3095793T
(lt)
|
2003-07-28 |
2020-07-10 |
Genentech, Inc. |
Baltymo a išplovimo sumažinimas afininės baltymo a chromatografijos metu
|
|
CA2536918A1
(en)
|
2003-08-26 |
2005-03-03 |
Leland Shapiro |
Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
|
|
MXPA06000176A
(es)
|
2003-12-10 |
2006-06-27 |
Millennium Pharm Inc |
Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
|
|
ES2362667T3
(es)
|
2004-01-09 |
2011-07-11 |
Pfizer Inc. |
ANTICUERPOS FRENTE A MAdCAM.
|
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
|
KR101364276B1
(ko)
|
2004-09-03 |
2014-02-20 |
제넨테크, 인크. |
인간화 항-베타７ 길항제 및 그의 용도
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US8916165B2
(en)
|
2004-12-15 |
2014-12-23 |
Janssen Alzheimer Immunotherapy |
Humanized Aβ antibodies for use in improving cognition
|
|
MY146381A
(en)
*
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
WO2007007151A2
(en)
*
|
2005-07-11 |
2007-01-18 |
Pfizer Limited |
Use of anti-mad-cam antibody for the treatment of emphysema
|
|
WO2007007160A2
(en)
*
|
2005-07-11 |
2007-01-18 |
Pfizer Limited |
Anti-madcam antibodies to treat fever
|
|
JP2009515552A
(ja)
*
|
2005-11-17 |
2009-04-16 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
α４β７インテグリン反応性ヒト化免疫グロブリン
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
|
US8163886B2
(en)
|
2006-12-21 |
2012-04-24 |
Emd Millipore Corporation |
Purification of proteins
|
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
|
KR101431856B1
(ko)
|
2007-01-22 |
2014-08-27 |
제넨테크, 인크. |
항체의 고분자전해질 침전 및 정제
|
|
EP2129397B1
(en)
*
|
2007-03-02 |
2018-10-31 |
Amgen, Inc. |
Methods and compositions for treating tumor diseases
|
|
EP2125892A2
(en)
*
|
2007-03-20 |
2009-12-02 |
Millennium Pharmaceuticals, Inc. |
Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
RU2540150C2
(ru)
|
2007-06-25 |
2015-02-10 |
Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк |
Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами
|
|
KR102055873B1
(ko)
|
2007-07-09 |
2019-12-13 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
|
US8613920B2
(en)
*
|
2007-07-27 |
2013-12-24 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
CN103554215B
(zh)
|
2007-10-30 |
2016-06-15 |
健泰科生物技术公司 |
通过阳离子交换层析进行的抗体纯化
|
|
HRP20141110T1
(hr)
*
|
2008-01-11 |
2015-01-16 |
Astellas Pharma Inc. |
Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
US8999702B2
(en)
|
2008-06-11 |
2015-04-07 |
Emd Millipore Corporation |
Stirred tank bioreactor
|
|
PT2848625T
(pt)
|
2008-08-14 |
2019-10-25 |
Genentech Inc |
Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena.
|
|
EP2334323A2
(en)
|
2008-09-10 |
2011-06-22 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
EP2358734A1
(en)
|
2008-12-16 |
2011-08-24 |
Millipore Corporation |
Purification of proteins
|
|
SG171446A1
(en)
|
2008-12-16 |
2011-07-28 |
Millipore Corp |
Stirred tank reactor and method
|
|
ES2547712T3
(es)
|
2009-02-27 |
2015-10-08 |
Genentech, Inc. |
Métodos y composiciones para el marcado de proteínas
|
|
AU2013205341B2
(en)
*
|
2009-03-20 |
2016-05-05 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
TWI466681B
(zh)
|
2009-03-20 |
2015-01-01 |
Amgen Inc |
α４β７雜二聚體專一性拮抗抗體
|
|
AU2016208453B2
(en)
*
|
2009-03-20 |
2018-02-22 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
KR101537840B1
(ko)
|
2009-05-13 |
2015-07-22 |
젠자임 코포레이션 |
항-인간 ｃｄ52 면역글루불린
|
|
KR20180010324A
(ko)
|
2009-08-11 |
2018-01-30 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
|
SI2473617T1
(sl)
|
2009-09-01 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A
|
|
US20110117087A1
(en)
|
2009-10-26 |
2011-05-19 |
Reinhard Franze |
Method for the production of a glycosylated immunoglobulin
|
|
RU2584232C2
(ru)
|
2010-03-22 |
2016-05-20 |
Дженентек, Инк. |
Композиции и способы, используемые для стабилизации белоксодержащих готовых форм
|
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
|
KR101726707B1
(ko)
|
2010-05-17 |
2017-04-13 |
이엠디 밀리포어 코포레이션 |
생체분자 정제용 자극 반응성 중합체
|
|
MX374851B
(es)
|
2010-05-28 |
2025-03-06 |
Genentech Inc |
Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa
|
|
CA2802756C
(en)
|
2010-06-24 |
2021-05-04 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
|
BR112013003279A2
(pt)
|
2010-08-13 |
2016-06-14 |
Genentech In |
“métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
|
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
|
EP3311834A1
(en)
|
2011-05-02 |
2018-04-25 |
Millennium Pharmaceuticals, Inc. |
Formulation for anti-alpha4beta7 antibody
|
|
EP2723370A4
(en)
|
2011-06-24 |
2015-06-03 |
Univ Colorado Regents |
COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
|
|
US10745468B2
(en)
|
2011-12-22 |
2020-08-18 |
Kota Biotherapeutics, Llc |
Compositions and methods for modified B cells expressing reassigned biological agents
|
|
MX360453B
(es)
|
2011-12-22 |
2018-11-01 |
Genentech Inc |
Cromatografia de membrana de intercambio ionico.
|
|
US10478508B2
(en)
*
|
2012-01-10 |
2019-11-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
|
|
EA034583B1
(ru)
*
|
2012-01-12 |
2020-02-21 |
Милленниум Фармасьютикалз, Инк. |
ПРИМЕНЕНИЯ АНТИ-α4β7 АНТИТЕЛА
|
|
RU2017139267A
(ru)
|
2012-03-27 |
2019-02-12 |
Дженентек, Инк. |
Усовершенствованные способы выделения рекомбинантных белков
|
|
CN103374073A
(zh)
*
|
2012-04-26 |
2013-10-30 |
中国科学院上海生命科学研究院 |
识别活化形式整合素α4β7的人源化单克隆抗体
|
|
HRP20250525T1
(hr)
|
2012-05-18 |
2025-06-20 |
Genentech, Inc. |
Visokokoncentrirane formulacije monoklonskog protutijela
|
|
US9393327B2
(en)
|
2012-12-19 |
2016-07-19 |
Genentech, Inc. |
Methods and compositions for radiohalogen protein labeling
|
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
|
WO2016007752A1
(en)
|
2014-07-09 |
2016-01-14 |
Genentech, Inc. |
Ph adjustment to improve thaw recovery of cell banks
|
|
WO2016057424A1
(en)
|
2014-10-06 |
2016-04-14 |
Chemocentryx, Inc. |
Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
|
|
WO2016086147A1
(en)
|
2014-11-26 |
2016-06-02 |
Millennium Pharmaceuticals, Inc. |
Vedolizumab for the treatment of fistulizing crohn's disease
|
|
WO2016105572A1
(en)
|
2014-12-24 |
2016-06-30 |
Millennium Pharmaceuticals, Inc. |
PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
|
|
MA41636A
(fr)
|
2015-03-06 |
2018-01-09 |
Millennium Pharm Inc |
Méthode de traitement de la cholangite sclérosante primitive
|
|
AU2016306320B2
(en)
*
|
2015-08-11 |
2022-04-14 |
Osaka University |
Antibody
|
|
CN108348581B
(zh)
*
|
2015-09-04 |
2022-07-01 |
斯克利普斯研究所 |
胰岛素免疫球蛋白融合蛋白
|
|
EP3397274A1
(en)
|
2015-12-31 |
2018-11-07 |
The Regents of the University of Colorado, a body corporate |
Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
|
|
EP3430053A1
(en)
*
|
2016-03-14 |
2019-01-23 |
Millennium Pharmaceuticals, Inc. |
Methods of treating or preventing graft versus host disease
|
|
MA44408A
(fr)
*
|
2016-03-14 |
2019-01-23 |
Millennium Pharm Inc |
Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
|
|
WO2017165778A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
TW201735949A
(zh)
|
2016-03-24 |
2017-10-16 |
千禧製藥公司 |
治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
|
|
EP3436610A1
(en)
|
2016-03-29 |
2019-02-06 |
Geltor, Inc. |
Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
|
|
US10918716B2
(en)
|
2016-05-04 |
2021-02-16 |
Millennium Pharmaceuticals, Inc. |
Triple combination therapy for treating Crohn's disease
|
|
WO2017214376A1
(en)
*
|
2016-06-10 |
2017-12-14 |
Elwha Llc |
Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
|
|
EP3468597A1
(en)
|
2016-06-12 |
2019-04-17 |
Millennium Pharmaceuticals, Inc. |
Method of treating inflammatory bowel disease
|
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
|
EP3558366A1
(en)
|
2016-12-22 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Methods and formulations for reducing reconstitution time of lyophilized polypeptides
|
|
KR20190141148A
(ko)
|
2017-04-28 |
2019-12-23 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
소아 장애를 치료하는 방법
|
|
MA48241A1
(fr)
|
2017-07-14 |
2021-03-31 |
Pfizer |
Anticorps dirigés contre madcam
|
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
|
PL3818078T3
(pl)
|
2018-07-03 |
2024-04-29 |
Bristol-Myers Squibb Company |
Metody produkcji białek rekombinowanych
|
|
US12415980B2
(en)
|
2018-10-10 |
2025-09-16 |
Boehringer Ingelheim International Gmbh |
Method for membrane gas transfer in high density bioreactor culture
|
|
WO2020113164A1
(en)
*
|
2018-11-30 |
2020-06-04 |
Memorial Sloan Kettering Cancer Center |
Heterodimeric tetravalency and specificity antibody compositions and uses thereof
|
|
EP3946457A1
(en)
|
2019-04-01 |
2022-02-09 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
|
SG11202111349QA
(en)
|
2019-04-12 |
2021-11-29 |
Geltor Inc |
Recombinant elastin and production thereof
|
|
EP3956358A4
(en)
*
|
2019-04-17 |
2023-01-25 |
Millennium Pharmaceuticals, Inc. |
COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
|
|
CN118909120A
(zh)
*
|
2019-06-10 |
2024-11-08 |
武田药品工业株式会社 |
抗体纯化方法及其组合物
|
|
KR20220019725A
(ko)
*
|
2019-06-10 |
2022-02-17 |
다케다 야쿠힌 고교 가부시키가이샤 |
항체를 생성하기 위한 세포 배양 방법 및 조성물
|
|
WO2021021973A1
(en)
|
2019-08-01 |
2021-02-04 |
Bristol-Myers Squibb Company |
Methods of improving protein productivity in fed-batch cell cultures
|
|
CN116194570A
(zh)
|
2020-09-22 |
2023-05-30 |
百时美施贵宝公司 |
用于产生治疗性蛋白的方法
|
|
US20250115666A1
(en)
|
2021-08-05 |
2025-04-10 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|
|
CN119731204A
(zh)
|
2022-06-16 |
2025-03-28 |
赛福伦有限责任公司 |
抗pd-1抗体-衰减的il-2免疫偶联物及其用途
|
|
AU2024282654A1
(en)
|
2023-05-30 |
2025-12-04 |
Paragon Therapeutics, Inc. |
Alpha4beta7 integrin antibody compositions and methods of use
|
|
WO2024252368A2
(en)
|
2023-06-09 |
2024-12-12 |
Takeda Pharmaceutical Company Limited |
Methods and compositions for treating ulcerative colitis
|
|
US20250195677A1
(en)
|
2023-12-19 |
2025-06-19 |
Cephalon Llc |
Uses for attenuated il-2 immunoconjugates
|
|
CN117777292B
(zh)
*
|
2023-12-28 |
2024-10-18 |
天津大学 |
抗整合素α4β7纳米抗体及其用途
|
|
WO2025149974A1
(en)
|
2024-01-11 |
2025-07-17 |
Takeda Pharmaceutical Company Limited |
Combination therapy with an anti-alpha4beta7 antibody
|
|
WO2025177214A1
(en)
|
2024-02-20 |
2025-08-28 |
Takeda Pharmaceutical Company Limited |
Therapeutic methods
|